FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFI	ICIAL OWNE	RSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GRAYZEL DAVID S.				2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [AVTE]									ck all applic Directo	tor		rson(s) to Issuer		
(Last) (First) (Middle) C/O AEROVATE THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/21/2022								Officer below)	(give title		Other (s below)	specify		
930 WINTER STREET, SUITE M-500				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) WALTH	AM M	A	02451								X							
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				?. Transacti Date Month/Day	Execution Date,		3. Transaction Code (Instr. 8) Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) Code (Instr. 5)		ed (A) o tr. 3, 4	4 and Securitie Benefici		es Form ally (D) o Following (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) or (D)	Pri	ce	Transact (Instr. 3 a	ction(s)			(111041. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any			Cod	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and of Securitic Underlying Derivative (Instr. 3 and			ies g Secur		3. Price of Derivative Security (Instr. 5)	derivative Securities Beneficial Owned Following Reported	Securities Beneficially Owned Following Reported Transaction(s)		11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Cod	e V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amor or Numl of Share	ber					
Stock Option (Right to Buy)	\$12.26	06/21/2022		A		12,500		(1)	0	6/20/2032	Common Stock	12,5	500	\$0	12,500)	D ⁽²⁾	

Explanation of Responses:

- 1. The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 21, 2023 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.
- 2. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

/s/ Ommer Chohan, Attorney-06/22/2022 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.